These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 22126567)

  • 81. Randomized phase II study of FEC day 1 + 8 and FEC day 1 in patients with advanced breast cancer.
    van Toorn DW; Nortier JW; Rubach M; de Swart CA; Huldij JC; van Tinteren H; Vermorke JB
    Breast Cancer Res Treat; 2000 Mar; 60(1):57-62. PubMed ID: 10845809
    [TBL] [Abstract][Full Text] [Related]  

  • 82. 5-Fluorouracil, epirubicin and cyclophosphamide (FEC combination) in advanced breast cancer.
    Zamagni C; Martoni A; Ercolino L; Baroni M; Tanneberger S; Pannuti F
    J Chemother; 1991 Apr; 3(2):126-9. PubMed ID: 1875232
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer.
    Jenkins P; Freeman S
    Ann Oncol; 2009 Jan; 20(1):34-40. PubMed ID: 18701428
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Effects of dose-intensive chemotherapy and radiotherapy on serum n-terminal proatrial natriuretic peptide in high-risk breast cancer patients.
    Hall KS; Wiklund T; Erikstein B; Holte H; Kvalheim G; Sommer HH; Andersen A; Skovlund E; Bergh J; Hall C
    Breast Cancer Res Treat; 2001 Jun; 67(3):235-44. PubMed ID: 11561769
    [TBL] [Abstract][Full Text] [Related]  

  • 85. [Equalization of breast cancer chemotherapy at general hospital( II )-evaluation of safety in FEC and TC regimens].
    Kitada N; Nishino M; Yasuda J; Morita S; Fujii C; Minegaki T; Kondoh M; Anami S; Takara K; Watari M
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1671-5. PubMed ID: 19838026
    [TBL] [Abstract][Full Text] [Related]  

  • 86. [Efficacy and safety of aprepitant in patients with breast cancer].
    Tagashira H; Matsuhisa T; Oze I; Kiyoto S; Takahashi M; Hara F; Takabatake D; Takashima S; Aogi K; Osumi S; Eguchi H
    Gan To Kagaku Ryoho; 2011 Aug; 38(8):1307-11. PubMed ID: 21829069
    [TBL] [Abstract][Full Text] [Related]  

  • 87. [Preventive effect of low-dose carvedilol combined with candesartan on the cardiotoxicity of anthracycline drugs in the adjuvant chemotherapy of breast cancer].
    Liu L; Liu ZZ; Liu YY; Zheng ZD; Liang XF; Han YL; Xie XD
    Zhonghua Zhong Liu Za Zhi; 2013 Dec; 35(12):936-40. PubMed ID: 24506965
    [TBL] [Abstract][Full Text] [Related]  

  • 88. [Use of G-CSF in dose-intensified chemotherapy of breast cancer with FEC (500/75/500 mg/m2 KO) in the adjuvant and metastatic situation].
    Konecny G; Nestle-Krämling C; Untch M
    Gynakol Geburtshilfliche Rundsch; 1993; 33 Suppl 1():301-2. PubMed ID: 7509677
    [No Abstract]   [Full Text] [Related]  

  • 89. A randomised comparative trial of infusional ECisF versus conventional FEC as adjuvant chemotherapy in early breast cancer: the TRAFIC trial.
    Sirohi B; A'Hern R; Coombes G; Bliss JM; Hickish T; Perren T; Crawford M; O'Brien M; Iveson T; Ebbs S; Skene A; Laing R; Smith IE
    Ann Oncol; 2010 Aug; 21(8):1623-1629. PubMed ID: 20093351
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Phase I trial of adjuvant chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil (CEF) for stage II breast cancer.
    Jones SE; Mennel RG; Peters GN; Westrick MA; Brooks BD; Knox SM; McGuffey P
    Invest New Drugs; 1988 Sep; 6(3):195-8. PubMed ID: 2847991
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Benefit of the addition of paclitaxel to standard chemotherapy with 5-fluorouracil/doxorubicin/cyclophosphamide in patients with operable breast cancer.
    Clin Breast Cancer; 2000 Oct; 1(3):189-90. PubMed ID: 11899642
    [No Abstract]   [Full Text] [Related]  

  • 92. Clinical study on safety of cantharidin sodium and shenmai injection combined with chemotherapy in treating patients with breast cancer postoperatively.
    Wang L; Huang XE; Cao J
    Asian Pac J Cancer Prev; 2014; 15(14):5597-600. PubMed ID: 25081671
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Primary medical (neo-adjuvant) chemotherapy for operable breast cancer.
    Smith IE; Jones AL; O'Brien ME; McKinna JA; Sacks N; Baum M
    Eur J Cancer; 1993; 29A(12):1796-9. PubMed ID: 8398318
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Acceptable cardiac safety profile of neoadjuvant 5-fluorouracil, epirubicin, cyclophosphamide and celecoxib (FEC-C) for breast cancer: a subanalysis of biomarkers for cardiac injury.
    Chow LW; Loo WT; Yip AY; Ng EL
    Int J Biol Markers; 2013 Apr; 28(1):E92-9. PubMed ID: 23592005
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study.
    Mozaffari F; Lindemalm C; Choudhury A; Granstam-Björneklett H; Lekander M; Nilsson B; Ojutkangas ML; Osterborg A; Bergkvist L; Mellstedt H
    Cancer Immunol Immunother; 2009 Jan; 58(1):111-20. PubMed ID: 18488220
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients.
    Zhou WB; Yin H; Liu XA; Zha XM; Chen L; Dai JC; Tao AD; Chen L; Ma JJ; Ling LJ; Wang S
    BMC Cancer; 2010 Jun; 10():281. PubMed ID: 20540745
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Feasibility study of FEC-chemotherapy with dose-intensive epirubicin as initial treatment in high-risk breast cancer.
    van der Wall E; Richel DJ; Kusumanto YH; Rutgers EJ; Schornagel JH; Schaake-Koning CC; Peterse JL; Rodenhuis S
    Ann Oncol; 1993 Nov; 4(9):791-2. PubMed ID: 8280661
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Role of taxanes in chemotherapy-related cognitive impairment: A prospective longitudinal study.
    Cerulla N; Arcusa À; Navarro JB; Garolera M; Enero C; Chico G; Fernández-Morales L
    Breast Cancer Res Treat; 2017 Jul; 164(1):179-187. PubMed ID: 28421379
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Cost-effectiveness analysis of breast cancer adjuvant treatment: FEC 50 versus FEC 100 (FASG05 study).
    Bonneterre J; Bercez C; Bonneterre ME; Lenne X; Dervaux B
    Ann Oncol; 2005 Jun; 16(6):915-22. PubMed ID: 15894546
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Tetracosactrin vs. methylprednisolone in the prevention of emesis in patients receiving FEC regimen for breast cancer.
    Bonneterre J; Kerbrat P; Fargeot P; Metz R; Roche H; Bastit P; Chevrier A; Tubiana-Hulin M; Geyer G; Cappelaere P
    Eur J Cancer; 1991; 27(7):849-52. PubMed ID: 1834115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.